Greenwich LifeSciences shares surged after the company reported positive results from its Phase III FLAMINGO-01 trial for an immunotherapy aimed at preventing breast cancer recurrence. The study showed about an 80% reduction in recurrence rates in the open-label non-HLA-A 02 arm, with results trending in line with earlier Phase IIb data, fuelling investor optimism.